Stocks and Investing Stocks and Investing
Wed, July 15, 2020

Matthew Harrison Maintained (BIIB) at Sell with Decreased Target to $263 on, Jul 15th, 2020


Published on 2024-10-27 09:38:47 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Sell with Decreased Target from $301 to $263 on, Jul 15th, 2020.

Matthew has made no other calls on BIIB in the last 4 months.



There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $273 on, Monday, June 22nd, 2020
  • Carter Gould of "Barclays" Downgraded from Buy to Hold and Decreased Target to $280 on, Monday, June 22nd, 2020
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold and Decreased Target to $297 on, Tuesday, June 9th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Hold with Decreased Target to $308 on, Friday, May 1st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Hold with Decreased Target to $310 on, Thursday, April 23rd, 2020


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Brian Skorney of "Baird" Maintained at Sell with Decreased Target to $228 on, Friday, June 19th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $350 on, Friday, April 24th, 2020
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $365 on, Thursday, April 23rd, 2020
  • Robyn Karnauskas of "SunTrust Robinson Humphrey" Maintained at Strong Buy with Decreased Target to $330 on, Thursday, April 23rd, 2020
  • Steven Seedhouse of "Citigroup" Downgraded from Hold to Strong Sell on, Thursday, April 23rd, 2020

Contributing Sources